RxDoctor Payments Data

Hossein Shenasa, MD

Interventional Cardiology · San Jose, CANPI 1942368444

Payments from drug & device makers

$20,394in general payments, 2019–2025

Across 349 payments — averaging $58.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biotronik Inc.$9K
  • Medtronic$3K
  • Boston Scientific$2K
  • Amarin Pharma, Inc.$1K
  • E.r. Squibb & Sons, L.L.C.$961
  • Johnson & Johnson$410
  • plus $3K from 18 others

What the payments were for

  • Travel & lodging$11,14955%
  • Food & beverage$8,92244%
  • Education$3232%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$20,394 in reported general payments places this provider in the 65th percentile of 585 interventional cardiology providers in California.

See all interventional cardiology providers in California

Medicare billing

Part B allowed, 2024
$1,819,887
Medicare patients
785
Services billed
7,954

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban385$523,437
XareltoRivaroxaban299$379,356
VascepaIcosapent Ethyl107$69,225
EntrestoSacubitril/Valsartan23$37,709
MultaqDronedarone Hcl33$37,435
Dofetilide121$28,532
Icosapent Ethyl38$15,298
Repatha SureclickEvolocumab16$12,544
Metoprolol Succinate733$10,772
Rosuvastatin Calcium296$8,010
Amiodarone Hcl91$5,891
Nebivolol Hcl77$5,546
Dabigatran EtexilateDabigatran Etexilate Mesylate13$5,360
Flecainide Acetate106$4,708
Propafenone Hcl95$4,577

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$337$523,437385 claims
Johnson & JohnsonXarelto$410$379,356299 claims
NovartisEntresto$290$37,70923 claims
Sanofi-aventis U.S. LLCMultaq$73$37,43533 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 585 interventional cardiology providers in California.

Other interventional cardiology in San Jose

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →